Synta Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Synta Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count).
Synta Pharmaceuticals: 21 sponsored US clinical trials, none currently recruiting.
Synta Pharmaceuticals sponsors 21 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 18 completed. 2 of these trials are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 1 trials.
Top-decile sponsor footprint
Synta Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#714 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
18 of 21 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
21 total, page 1 of 1
A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
NCT01798485
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
NCT01677455
A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT01562015
Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer
NCT01348126
A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors
NCT01183364
A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)
NCT01039519
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
NCT01031225
A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia
NCT00964873
STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders
NCT00858572
A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer
NCT00808418
Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors
NCT00687934
Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma
NCT00522834
Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease
NCT00234741
Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease
NCT00138840
A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas
NCT00087997
A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors
NCT00276913
STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma
NCT00084214
STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)
NCT00088088
STA-5326 in Crohn's Disease Patients
NCT00088062
STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors
NCT00088101
STA-4783 and Paclitaxel for Treatment of Solid Tumors
NCT00088114
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 8 |
| Phase 3 | 2 |
Therapeutic Areas
How the Synta Pharmaceuticals early-phase archive is shaped
21 indexed studies, none listed as recruiting (0% open); 18 completed (86%).
Phase mix: 2 late (III/IV) vs 19 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Synta Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 21 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Synta Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 21 archived trials
- AEterna Zentaris · 21 trials · 0% recruiting
- Amphastar Pharmaceuticals · 21 trials · 5% recruiting
- Apellis Pharmaceuticals · 21 trials · 10% recruiting
- Array Biopharma, now a wholly owned subsidiary of Pfizer · 21 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Synta Pharmaceuticals page
21 registered trials is a research-attention snapshot, not an endorsement of Synta Pharmaceuticals or any single study.
- None of Synta Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Prostate Cancer is the condition Synta Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Synta Pharmaceuticals pipeline card: 21 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.